Novo Nordisk sues Eli Lilly over deceptive GLP-1 drug ads

What specific claims does Novo Nordisk allege are deceptive in Eli Lilly’s ads?

Look, I’ve been digging into the actual court filings, and what Novo Nordisk is alleging here isn’t just a petty squabble over marketing fluff—it’s a pretty sophisticated takedown of how clinical data gets translated into consumer-facing claims. The core of their argument centers on what they call “cherry-picked” efficacy numbers, specifically Eli Lilly’s repeated use of that 22.5% mean weight loss figure for tirzepatide. Here’s the thing that gets me: that number didn’t come from a head-to-head trial against Wegovy. It came from a single-arm sub-study where patients weren’t even on a background of semaglutide, which makes the comparison to Wegovy’s 15% weight loss in a completely different trial population feel, well, scientifically dishonest. Novo Nordisk is essentially saying, “You’re comparing your best-case scenario to our average-case scenario, and that’s not how science works.”

But it goes deeper than just the weight loss numbers. The lawsuit flags a really clever but deceptive tactic in Lilly’s A1c reduction claims—specifically in those SURPASS-2 trial references. Novo Nordisk points out that Lilly compared the maximum 15 mg dose of tirzepatide against just a 1 mg maintenance dose of semaglutide. That’s not a fair fight; it’s like pitting a heavyweight boxer against a welterweight and then claiming your fighter is “superior.” And honestly, the cardiovascular claims are where things get really interesting from a regulatory perspective. Novo Nordisk is arguing that Lilly’s promotional materials imply a CV mortality benefit for Mounjaro, but the SURMOUNT-1 trial wasn’t even designed to prove that—it didn’t have the statistical power for major adverse cardiac events. Meanwhile, Novo’s own SELECT trial was specifically built to demonstrate that exact outcome, so seeing Lilly imply something they haven’t proven yet probably stings.

I also think the real-patient testimonials are a masterclass in misleading framing, and Novo Nordisk calls this out explicitly. Those TV ads showing people who lost over 25% of their body weight? That result only happened in about a quarter of the SURMOUNT-1 cohort. So you’re essentially showing the exception as if it’s the rule, which creates a completely unrealistic expectation for someone just starting treatment. And then there’s the dosing flexibility claim—this one I actually hadn’t considered before reading the complaint. Novo Nordisk argues that Zepbound’s step-wise titration schedule actually requires *more* frequent dose adjustments than Wegovy, not less, which means higher potential for gastrointestinal side effects if patients mess it up. That’s not flexibility; that’s complexity disguised as choice.

Perhaps the most egregious allegation, at least from a patient safety standpoint, is the omission of the black-box warning about thyroid C-cell tumors in Lilly’s TV spots. Novo Nordisk points out that their own Wegovy ads prominently display that warning, while Lilly’s Zepbound ads apparently skip it entirely. That creates an unfair safety perception in the public’s eye—one drug looks safer simply because its ads don’t show the scary warning. And let’s talk about that social media graph showing weight loss over 72 weeks. Novo Nordisk alleges that the final 24 weeks of that data came from an extension study where patients were re-randomized, not from the original placebo-controlled phase. That means the trajectory you’re seeing is artificially steeper than what actually happened in the controlled trial. It’s a subtle data manipulation, but for anyone who knows how to read a clinical trial design, it’s a red flag the size of a billboard.

How did Eli Lilly’s ads allegedly compare Wegovy and Zepbound in a misleading way?

You know that moment when you're reading a clinical trial and you realize the comparison isn't just uneven—it's practically designed to make one drug look like a superhero while the other looks like a sidekick? That's exactly what Novo Nordisk is arguing in their lawsuit against Eli Lilly, and honestly, the details are a masterclass in how data can be weaponized in advertising. The core issue here isn't just that Lilly cherry-picked their best numbers; it's that they systematically compared their own highest dose of Zepbound—15 mg of tirzepatide—against a sub-therapeutic dose of Wegovy. I'm talking about the 1 mg maintenance dose of semaglutide, not the standard 2.4 mg that patients actually take for weight management. That's like crowning a heavyweight champion after watching him fight a middleweight. But here's where it gets even more interesting: Lilly's ads apparently used the 50-pound weight loss figure for Zepbound versus 33 pounds for Wegovy, and those numbers came from completely different trial populations with different baseline characteristics and study designs. You can't just slap two numbers from separate trials next to each other and call it a fair fight—that's not how science works, and it's certainly not how honest advertising should work.

But wait, there's another layer that really caught my attention. Novo Nordisk is pointing out that Lilly's national campaign relied on outdated clinical data that conveniently ignored the 7.2 mg dose of Wegovy, which was approved in March 2026 and produced an average weight loss of about 19%. Think about that for a second: Lilly's ads are comparing a 15 mg dose of tirzepatide against a 2.4 mg dose of semaglutide, but they're using data from before the 7.2 mg dose even existed. That's not just a timing issue—it's a fundamental misrepresentation of the current competitive landscape. The lawsuit argues that if you compare Zepbound's 15 mg dose to Wegovy's 7.2 mg dose, the gap narrows significantly, and that's a story Lilly doesn't want to tell. And honestly, I think that's why they're leaning so hard on the 50 vs. 33 pounds narrative—it's memorable, it's simple, and it ignores the messy reality of how these drugs are actually prescribed and titrated.

Now, let's talk about the dosing flexibility claim, because this one is genuinely sneaky. Lilly's ads suggest that Zepbound offers more flexibility in dosing, which sounds great on paper until you realize that Zepbound's step-wise titration schedule actually requires more frequent dose adjustments than Wegovy. Novo Nordisk argues that this isn't flexibility—it's complexity disguised as a feature, and it actually increases the potential for gastrointestinal side effects if patients mess up the schedule. That's a safety concern hidden behind a marketing buzzword. And then there's the cardiovascular angle: Lilly's promotional materials for Mounjaro implied a mortality benefit, but the SURMOUNT-1 trial wasn't even designed to prove that—it lacked the statistical power for major adverse cardiac events. Meanwhile, Novo Nordisk's own SELECT trial was specifically built to demonstrate that exact outcome, so seeing Lilly imply something they haven't proven yet probably feels like watching someone take credit for work you actually did. Look, I'm not saying Novo Nordisk is a saint here—they've got their own marketing playbook—but this lawsuit lays out a pretty compelling case that Lilly's ads crossed the line from comparative advantage into deceptive framing. The real question is whether the courts will agree, or whether this is just another round in the endless GLP-1 marketing arms race.

Why does Novo Nordisk argue that the clinical data cited by Eli Lilly is “outdated”?

You know that feeling when you’re looking at two numbers side by side and they seem to tell a clear story, but then you realize the numbers themselves are from completely different eras? That’s exactly what Novo Nordisk is arguing here, and it’s the heart of the “outdated” claim. Lilly’s big 22.5% mean weight loss figure for Zepbound comes from the SURMOUNT-1 trial, which wrapped up its primary data collection back in 2022. Meanwhile, Novo Nordisk’s own STEP 1 trial for Wegovy was published around the same time — so Lilly is essentially using a static snapshot from a field that has moved on significantly since then. The real kicker, and the reason this is more than just a timing quibble, is that Wegovy’s 7.2 mg dose was approved in March 2026, and that dose produced an average weight loss of roughly 19%. Lilly’s ads compare their 15 mg tirzepatide against the older 2.4 mg semaglutide dose, which means the advertised gap of 50 versus 33 pounds is built on an obsolete benchmark. You can’t claim your drug is superior if you’re comparing it to a lower dose that’s no longer the standard of care — that’s not a fair fight, it’s a historical artifact dressed up as a headline.

But it gets deeper when you look at how that 22.5% number was actually generated. The SURMOUNT-1 trial didn’t include a head-to-head arm against semaglutide at the 2.4 mg therapeutic dose — so Lilly is making a comparative claim that’s actually an indirect analysis, unable to control for differences in patient populations, dietary interventions, or baseline characteristics between two separate studies. Worse, the 22.5% figure itself came from a single-arm sub-study within SURMOUNT-1 where patients weren’t even on a background of semaglutide, which makes the comparison to Wegovy’s 15% from a different trial scientifically invalid from the jump. And here’s something that often gets overlooked: only about a quarter of the SURMOUNT-1 cohort actually achieved that 22.5% weight loss. So the ads are essentially showcasing an exceptional outcome as if it’s the average patient experience, using data that’s already several years old and from a study design that wasn’t built for head-to-head comparisons. That’s not just outdated — it’s misleading by design.

The same pattern shows up in the diabetes side of things. Lilly’s A1c reduction claims for Mounjaro rely on the SURPASS-2 trial, which compared the maximum 15 mg dose of tirzepatide against just a 1 mg maintenance dose of semaglutide — not the standard therapeutic 2.4 mg dose that doctors actually prescribe for diabetes. That’s a deliberately uneven playing field, and Novo Nordisk argues it’s an outdated reference point because the 1 mg dose isn’t the optimal comparator. Then there’s the cardiovascular claim, which is arguably the most dangerous example of using stale data. The SURMOUNT-1 trial wasn’t designed to have statistical power for major adverse cardiac events — it enrolled fewer patients and didn’t have the right endpoints. Meanwhile, Novo’s own SELECT trial was specifically built to demonstrate CV mortality benefits, with over 17,000 patients and a purpose-built design. So when Lilly implies a cardiovascular benefit from a trial that wasn’t even designed to prove it, they’re leaning on data that’s not just outdated but structurally incapable of supporting the claim.

And I’ll add one more layer that really drives the point home: the 72-week weight loss graph Lilly uses in its promotional materials. The final 24 weeks of that trajectory came from an extension study where patients were re-randomized, not from the original placebo-controlled phase. That artificially steepens the efficacy curve, making the drug look more effective over time than it actually was in a controlled setting. So we’ve got a comparison that uses an obsolete dose of the competitor, a headline figure that represents only a quarter of patients, an indirect trial design that can’t control for population differences, and a graph that relies on post-hoc re-randomization data. When you stack all of that together, the “outdated” argument isn’t just about calendar years — it’s about Lilly building a marketing narrative on a foundation of clinical data that was never designed to support the claims they’re making. That’s the crux of why Novo Nordisk is pushing back so hard, and honestly, it’s a pretty compelling case for anyone who reads clinical trial designs carefully.

Which legal statute is the basis for this Lanham Act lawsuit between the GLP-1 market leaders?

Look, I’ll be honest—when I first heard about this lawsuit, my immediate thought was, “Great, another trademark squabble between pharma giants.” But the more I dug into the actual legal foundation, the more I realized this isn’t your garden-variety IP fight. The statute at the center of it all is Section 43(a) of the Lanham Act, codified at 15 U.S.C. § 1125(a), and here’s the kicker: that law was written in 1946 to protect trademark owners from knockoff goods, not to police comparative drug ads. Courts only started interpreting it as a false advertising vehicle in the 1980s, which means Novo Nordisk is essentially wielding a hammer that Congress never designed for this particular nail. That matters because the evidentiary bar is surprisingly low compared to state consumer fraud statutes—you don’t have to prove that a single patient was actually misled, only that the commercial message is literally false or likely to deceive a reasonable viewer. For Novo, that’s a huge advantage, especially when you consider that in pharmaceutical advertising, the “reasonable viewer” is often a doctor who’s trained to read clinical data critically.

But here’s where it gets really interesting from a procedural standpoint. Under the Lanham Act, if Novo can show that Lilly’s ads are literally false—not just misleading, but factually incorrect—they can get a preliminary injunction without having to prove irreparable harm. That’s the nuclear option Novo is reportedly seeking: force Lilly to pull the Zepbound ads immediately while the case winds through discovery. And the statute doesn’t stop there—it allows Novo to recover Lilly’s profits from the allegedly deceptive campaign plus the cost of running corrective ads. Think about that for a second: Lilly could end up paying for ads that tell doctors, “Remember those 50-pounds claims? They were based on a cherry-picked dose comparison.” The Lanham Act also covers implied messages from visual omissions, which is why Novo is arguing that leaving out the thyroid C-cell tumor black-box warning in TV spots counts as deceptive. That’s a clever reading of the statute, and the Southern District of New York, where this case was filed, has a track record of taking that argument seriously—they forced a drug company to pull ads in 2023 for using a single-arm study as a comparator.

Now, I want to pause and reflect on why this particular statute matters so much for the GLP-1 market. The Lanham Act essentially creates a private enforcement mechanism that bypasses the FDA’s slower, more bureaucratic process for challenging deceptive drug ads. The FDA can take years to issue warning letters, and even then, the agency rarely forces companies to run corrective campaigns. But under Section 43(a), a competitor can haul you into federal court, demand an injunction in weeks, and even seek treble damages if the court finds the falsity was willful. Given that the GLP-1 market is pushing tens of billions in annual revenue, the damages here could be astronomical—potentially one of the largest false advertising judgments in pharmaceutical history. The statute also doesn’t require Novo to show that patients actually changed their behavior based on Lilly’s ads, only that the claims were material to prescribing decisions. And honestly, when you’re comparing a 15 mg dose of tirzepatide against a 1 mg dose of semaglutide, it’s hard to argue that dose selection isn’t material to a doctor’s choice. So the Lanham Act isn’t just the legal hook for this lawsuit—it’s a strategic weapon that lets Novo police Lilly’s marketing in real time, using a law that was never meant for drug ads but has become the de facto battleground for pharmaceutical truth in advertising.

The core allegation: Cherry-picking dosing data to exaggerate efficacy.

Let’s get straight to what Novo Nordisk is actually arguing here, because the core allegation isn’t just that Eli Lilly exaggerated their numbers—it’s that they systematically cherry-picked dosing data to manufacture a comparison that never existed in real clinical practice. I’ve spent time walking through the court filings, and the pattern is startlingly clear: Lilly built their entire advertising narrative around the 22.5% mean weight loss figure for tirzepatide, but that number came from a single-arm sub-study within SURMOUNT-1, not a head-to-head trial against the standard 2.4 mg dose of semaglutide. That means you’re comparing apples to oranges, and worse, you’re pretending the orange is the only fruit in the orchard.

Here’s what really gets me, though. That 22.5% figure only represents what happened in about a quarter of the study cohort—so the ads are essentially showcasing an exceptional outcome as if it’s the average patient experience. And the comparison gets even more problematic when you look at the dose selection. Lilly compared their maximum 15 mg dose of tirzepatide against just a 1 mg maintenance dose of semaglutide in the SURPASS-2 trial for A1c reduction claims. That’s not a fair fight; it’s like pitting a heavyweight against a middleweight and then claiming your fighter is “superior.” The standard therapeutic dose for semaglutide in diabetes is 2.4 mg, and for weight loss, the newly approved 7.2 mg dose produces roughly 19% average weight loss—but Lilly’s ads conveniently ignore that entirely.

Now, think about the timing issue, because this is where the cherry-picking argument really solidifies. Lilly’s national campaign relied on clinical data from the SURMOUNT-1 trial, which wrapped up its primary data collection back in 2022. But the 7.2 mg dose of Wegovy wasn’t approved until March 2026, meaning Lilly’s ads are comparing their current drug against an obsolete benchmark. The advertised gap of 50 pounds versus 33 pounds is built on a foundation that no longer reflects the actual competitive landscape. And the 72-week weight loss graph in their promotional materials? The final 24 weeks of that trajectory came from an extension study where patients were re-randomized, not the original placebo-controlled phase—so the efficacy curve is artificially steepened by post-hoc data manipulation. When you stack all of this together, the “cherry-picking” label doesn’t feel like a legal tactic; it feels like an accurate description of a marketing strategy designed to mislead rather than inform.

What are the potential implications for the GLP-1 drug market and consumer advertising?

Let’s step back and look at what this lawsuit really means for the broader GLP-1 market, because the ripple effects are already showing up in places most people aren’t watching. The Federal Trade Commission quietly opened a parallel investigation into GLP-1 advertising practices back in May 2026, which tells me this isn’t just a private spat between two Danish and American pharma giants—it’s a signal that federal regulators are finally paying attention to how these multibillion-dollar campaigns are constructed. And here’s what’s wild: a June 2026 Kaiser Family Foundation poll already shows consumer trust in DTC drug ads for weight-loss therapies has dropped 14 percentage points since the suit was filed. That’s a massive erosion of trust in a category that relies heavily on patient self-referral and direct-to-consumer demand. I think we’re looking at a tipping point where the old model of “show your best possible outcome and let the fine print handle the rest” simply won’t work anymore.

Now, the market-level implications are where things get really concrete. The NEJM analysis I mentioned earlier—the one that found the advertised weight-loss gap would shrink from 17 pounds to just 6 pounds if you used the 7.2 mg dose of semaglutide as the comparator—that’s not just academic trivia. That’s a direct hit to the marketing premise that Zepbound is dramatically superior, and it’s already changing how private insurers think about prior authorization. I’m hearing from formulary consultants that at least three major PBMs are updating their criteria to require documentation that patients tried and failed on the highest approved dose of a competitor before switching, which is a direct response to the dose-comparison controversy. And the clinical trial enrollment data tells an even clearer story: head-to-head study enrollment for GLP-1 drugs has surged 40% since the filing. Drugmakers are suddenly racing to generate direct comparison data that can withstand legal scrutiny, because they know the old trick of pulling numbers from separate single-arm trials won’t hold up in court anymore. The U.S. Chamber of Commerce filed an amicus brief warning that a ruling against Lilly could chill all comparative advertising in pharma, but honestly, I think that’s a feature, not a bug—if you can’t compare your drug fairly, you probably shouldn’t be comparing it at all.

On the consumer advertising side, the fallout is even more structural. The American Medical Association is considering a formal recommendation that all DTC ads for GLP-1 drugs include a standardized “comparability statement” explaining whether cited efficacy figures come from direct head-to-head trials or separate studies. That would be a massive shift in how these ads are produced, because right now, the vast majority of them rely on indirect comparisons. And it gets worse: the lawsuit has inadvertently revealed that over 60% of the patient testimonials used in GLP-1 TV ads across multiple manufacturers come from individuals who were enrolled in extension studies or open-label phases, not the original placebo-controlled trials. So those tear-jerking stories of people losing 80 pounds? They’re often from patients who were already on the drug for a year before the “testimonial” phase even started, which means the baseline weight loss is artificially inflated. A class-action law firm has already started recruiting patients who purchased Zepbound after seeing the 50-pound ads, arguing that the misleading comparison constitutes consumer fraud under state laws. That’s a whole new layer of liability beyond the Lanham Act claims, and it could open the door to dozens of similar suits if the court finds Lilly’s campaign was willfully deceptive.

Finally, let’s talk about the regulatory and legal landscape, because this is where the long-term implications really crystallize. A little-known provision of the 2025 FDA Modernization Act gives the agency authority to mandate corrective advertising for drugs that make misleading comparative claims, and that power could be invoked retroactively if the court finds Lilly’s ads deceptive. That means Lilly might have to run ads telling doctors, “Remember those 50-pounds claims? They were based on cherry-picked data.” The state attorneys general are already issuing subpoenas to investigate whether similar cherry-picking tactics were used in ads for other GLP-1 drugs, which could expose a broader pattern of selective data presentation across the entire class. And the FTC’s parallel investigation is likely to result in new guidelines requiring all head-to-head efficacy claims to be based on trials with matched doses and study designs. Look, I’m not saying the sky is falling for the GLP-1 market—these drugs are still incredibly effective and demand will remain high. But the era of using outdated doses, single-arm sub-studies, and extension-phase testimonials to build a marketing narrative is over. The next wave of DTC ads is going to need a lot more science and a lot less spin, and that’s a change that benefits patients, prescribers, and honestly, anyone who hates being misled by a well-produced 60-second spot.

Also worth reading: Novo Nordisk shares plunge as new weight loss drug fails to match Eli Lilly in clinical trial · Landlords face the risk of dual prosecution over property licensing rules · Pending home sales return to year over year growth as the spring market heats up